ILT7/CD85g/LILRA4 Antibody (656656) [Alexa Fluor® 532]

• Reactivity: Hu
• Applications: B/N
• Clone: 656656
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 532

ILT7/CD85g/LILRA4 Antibody (656656) [Alexa Fluor® 532] Summary

• Immunogen: Mouse myeloma cell line, NS0­derived human LILRA4/CD85g/ILT7
  Glu24-Asn446
  Accession # P59901
• Specificity: Detects human LILRA4/CD85g/ILT7 in ELISA. No cross-reactivity with human LILRA1, LILRA2, LILRA3, LILRA5, LILRA6, LILRB2 and LILRB3 with ELISA was observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Neutralization

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ILT7/CD85g/LILRA4 Antibody (656656) [Alexa Fluor® 532]

• CD85 antigen-like family member G
• CD85g antigen
• CD85g
• ILT7
• ILT-7
• ILT7MGC129598
• Immunoglobulin-like transcript 7
• leukocyte immunoglobulin-like receptor subfamily A member 4
• leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4
• leukocyte immunoglobulin-like receptor, subfamily A (without TM domain), member4
• LILRA4
• MGC129597

Background

LILRA4, also known as ILT7 and CD85g, is an approximately 60-70 kDa variably glycosylated transmembrane protein that regulates immune cell activation (1). Mature human LILRA4 consists of a 423 amino acid (aa) extracellular domain (ECD) with four immunoglobulin-like domains, a 21 aa transmembrane segment, and a 32 aa cytoplasmic domain (2). Alternative splicing generates an additional isoform that lacks the signal peptide and a portion of the first Ig-like domain. LILRA4 is expressed on plasmacytoid dendritic cells (pDC) but is down-regulated in response to TLR9 signaling (3-5). Antibody mediated crosslinking of LILRA4 on pDC inhibits the production of type I interferons following TLR7 or TLR9 stimulation (3, 4, 6). It also blocks the up-regulation of CCR7 but enhances the up-regulation of Integrin  beta 7 on TLR7/9-stimulated pDC (6). LILRA4 associates with the ITAM-containing adaptor protein Fc epsilon RI gamma (3, 4, 6), and this complex binds to cell surface BST2/Tetherin which is expressed on monocytes, plasmacytoid and myeloid dendritic cells, B cells, and activated CD4⁺ and CD8⁺ T cells (5, 8). This interaction inhibits the TLR-induced pDC production of type I interferons, IL-6, and TNF-alpha (8).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.